Skip to content

SION SION Investment Proceeds

Investment Proceeds at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$221.24M+191%

Other financials

Income statement

See full
Operating income-$29.6M-50.6%
Net income-$26.8M-62.5%
EPS (diluted)-$0.60+3.2%

Balance sheet

See full
Cash & equivalents$64.3M-23.2%
Total debt$8.4M-11.8%
Total equity$288.2M-18.1%
Total assets$305.0M-17.5%

Cash flow

See full
Operating cash flow-$21.8M-34.1%
CapEx--100%
Free cash flow-$21.8M-33.4%

Valuation

See full
Market cap$1.86B

Returns & leverage

See full
Return on equity-26.7%
Debt / equity0.0×
Current ratio22.6×-6.1×

Where this comes from

Reported directly by SION in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.

The official record: SION’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SION's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SION's investment proceeds?
SION (SION) reported investment proceeds of $50.15M in Q1 2026.
How has SION's investment proceeds changed year-over-year?
SION's investment proceeds increased by 64.5% year-over-year, from $30.49M to $50.15M.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.